CD40 and neoplasm: Macrophage activation with anti-CD40 antibodies could be combined with other macrophage-activating agents, such as, CpG-containing oligodeoxynucleotides that may act by affecting the effector functions of TAMs to convert them from the M2 pro-tumor phenotype to M1 antitumor phenotype [106].